Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA-SRV Trial.

J Am Heart Assoc · 2025 · PMC12229194 · PMID 40439149

Europe PMC DOI

hedged sentence

0.3230

closest p · 6.5× alpha

0.3230

boldest claim

The sentences

did not reach statistical significanceP =0.323not close (p > 0.1)

6 However, this result likely did not reach statistical significance because of the size of our cohort ( P =0.323).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.